Revelation Biosciences Unveils Positive Clinical Data for Gemini in Kidney Disease Treatment

Reuters

Jan 14

<a href="https://laohu8.com/S/REVBU">Revelation Biosciences</a> Unveils Positive Clinical Data for Gemini in Kidney Disease Treatment

Revelation Biosciences Inc. has announced that new clinical data on its investigational drug Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide targeting acute kidney injury (AKI) and chronic kidney disease (CKD), will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego from March 29 to April 1, 2026. The upcoming presentation will include additional positive data from the recently completed PRIME clinical study, demonstrating normalization of the hyperinflammatory state in stage 3 and 4 CKD patients and restoration of immunocompetence. The data will be presented by Robin Marsden, Senior Vice President of Biology at Revelation Biosciences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126966) on January 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603361148"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603361148\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603361148?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603361148","market":"fut","top_or_hot":-1,"title":"Revelation Biosciences Unveils Positive Clinical Data for Gemini in Kidney Disease Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/REVBU\">Revelation Biosciences</a> Unveils Positive Clinical Data for Gemini in Kidney Disease Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/REVB\">Revelation Biosciences</a> Inc. has announced that new clinical data on its investigational drug Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide targeting acute kidney injury (AKI) and chronic kidney disease (CKD), will be presented at the International Conference on Advances in Critical Care Nephrology (AKI &amp; CRRT 2026) in San Diego from March 29 to April 1, 2026. The upcoming presentation will include additional positive data from the recently completed PRIME clinical study, demonstrating normalization of the hyperinflammatory state in stage 3 and 4 CKD patients and restoration of immunocompetence. The data will be presented by Robin Marsden, Senior Vice President of Biology at <a href=\"https://laohu8.com/S/REVBW\">Revelation Biosciences</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126966) on January 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revelation Biosciences Unveils Positive Clinical Data for Gemini in Kidney Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevelation Biosciences Unveils Positive Clinical Data for Gemini in Kidney Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-14 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/REVBU\">Revelation Biosciences</a> Unveils Positive Clinical Data for Gemini in Kidney Disease Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/REVB\">Revelation Biosciences</a> Inc. has announced that new clinical data on its investigational drug Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide targeting acute kidney injury (AKI) and chronic kidney disease (CKD), will be presented at the International Conference on Advances in Critical Care Nephrology (AKI &amp; CRRT 2026) in San Diego from March 29 to April 1, 2026. The upcoming presentation will include additional positive data from the recently completed PRIME clinical study, demonstrating normalization of the hyperinflammatory state in stage 3 and 4 CKD patients and restoration of immunocompetence. The data will be presented by Robin Marsden, Senior Vice President of Biology at <a href=\"https://laohu8.com/S/REVBW\">Revelation Biosciences</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126966) on January 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL4S4WMz:1","article_id":"2603361148","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603361148","pubTimestamp":1768399243,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Revelation Biosciences Inc. has announced that new clinical data on its investigational drug Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide targeting acute kidney injury  and chronic kidney disease , will be presented at the International Conference on Advances in Critical Care Nephrology  in San Diego from March 29 to April 1, 2026. The upcoming presentation will include additional positive data from the recently completed PRIME clinical study, demonstrating normalization of the hyperinflammatory state in stage 3 and 4 CKD patients and restoration of immunocompetence. The data will be presented by Robin Marsden, Senior Vice President of Biology at Revelation Biosciences.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","REVB":"Revelation Biosciences, Inc."},"translate_title":"Revelation Biosciences公布Gemini治疗肾脏疾病的积极临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REVB":0.9},"content_text":"Revelation Biosciences Unveils Positive Clinical Data for Gemini in Kidney Disease Treatment\n    \n\nRevelation Biosciences Inc. has announced that new clinical data on its investigational drug Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide targeting acute kidney injury (AKI) and chronic kidney disease (CKD), will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego from March 29 to April 1, 2026. The upcoming presentation will include additional positive data from the recently completed PRIME clinical study, demonstrating normalization of the hyperinflammatory state in stage 3 and 4 CKD patients and restoration of immunocompetence. The data will be presented by Robin Marsden, Senior Vice President of Biology at Revelation Biosciences.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126966) on January 14, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}